Amneal Pharmaceuticals Statistics
Want to see AMRX full AI Analyst Report?
Amneal Pharmaceuticals (AMRX) Stock Statistics & Valuation Metrics
Total Valuation
Amneal Pharmaceuticals has a market cap or net worth of $7.45B. The enterprise value is $9.98B.
- Market Cap
- $7.45B
- Enterprise Value
- $9.98B
Share Statistics
Amneal Pharmaceuticals has 348,412,720 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 348,412,720
- Owned by Insiders
- 36.76%
- Owned by Institutions
- 39.15%
Financial Efficiency
Amneal Pharmaceuticals’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is 13.80%.
- Return on Equity (ROE)
- -1.02
- Return on Assets (ROA)
- 0.02
- Return on Invested Capital (ROIC)
- 13.80%
- Return on Capital Employed (ROCE)
- 0.15
- Revenue Per Employee
- 346.98K
- Profits Per Employee
- 8,282.414
- Employee Count
- 8,700
- Asset Turnover
- 0.82
- Inventory Turnover
- 3.11
Valuation Ratios
The current PE Ratio of Amneal Pharmaceuticals is 49.72. Amneal Pharmaceuticals’s PEG ratio is 0.02.
- PE Ratio
- 49.72
- PS Ratio
- 2.33
- PB Ratio
- 13.51
- Price to FCF
- 184.36
- Price to Operating Cash Flow
- 39.31
- PEG Ratio
- 0.02
Income Statement
In the last 12 months, Amneal Pharmaceuticals had revenue of 3.02B and earned 72.06M in profits. Earnings per share was 0.23.
- Revenue
- 3.02B
- Gross Profit
- 1.14B
- Operating Income
- 423.09M
- Pretax Income
- 139.21M
- Net Income
- 72.06M
- EBITDA
- 603.87M
- Earnings Per Share (EPS)
- 0.23
Cash Flow
In the last 12 months, operating cash flow was 182.61M and capital expenditures -142.20M, giving a free cash flow of 40.41M billion.
- Operating Cash Flow
- 182.61M
- Free Cash Flow
- 40.41M
- Free Cash Flow per Share
- 0.12
Dividends & Yields
Amneal Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.55%
- Earnings Yield
- 2.08%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- 85.59%
- 50-Day Moving Average
- 19.71
- 200-Day Moving Average
- 16.13
- Relative Strength Index (RSI)
- 58.99
- Average Volume (3m)
- 3.05M
Important Dates
Amneal Pharmaceuticals upcoming earnings date is Feb 26, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Feb 26, 2027
- Ex-Dividend Date
- ―
Financial Position
Amneal Pharmaceuticals as a current ratio of 2.17, with Debt / Equity ratio of -3865.40%
- Current Ratio
- 2.17
- Quick Ratio
- 1.48
- Debt to Market Cap
- 0.67
- Net Debt to EBITDA
- 4.02
- Interest Coverage Ratio
- 1.75
Taxes
In the past 12 months, Amneal Pharmaceuticals has paid 11.28M in taxes.
- Income Tax
- 11.28M
- Effective Tax Rate
- 0.08
Enterprise Valuation
Amneal Pharmaceuticals EV to EBITDA ratio is 15.71, with an EV/FCF ratio of 259.56.
- EV to Sales
- 3.28
- EV to EBITDA
- 15.71
- EV to Free Cash Flow
- 259.56
- EV to Operating Cash Flow
- 57.43
Balance Sheet
Amneal Pharmaceuticals has $157.40M in cash and marketable securities with $3.28B in debt, giving a net cash position of -$3.13B billion.
- Cash & Marketable Securities
- $157.40M
- Total Debt
- $3.28B
- Net Cash
- -$3.13B
- Net Cash Per Share
- -$8.97
- Tangible Book Value Per Share
- -$5.01
Margins
Gross margin is 40.24%, with operating margin of 15.61%, and net profit margin of 4.62%.
- Gross Margin
- 40.24%
- Operating Margin
- 15.61%
- Pretax Margin
- 6.93%
- Net Profit Margin
- 4.62%
- EBITDA Margin
- 20.90%
- EBIT Margin
- 14.84%
Analyst Forecast
The average price target for Amneal Pharmaceuticals is $24.83, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- $24.83
- Price Target Upside
- 16.15% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 6
- Revenue Growth Forecast
- 8.88%
- EPS Growth Forecast
- 2272.07%
Scores
- Smart Score
- 10
- AI Score
- 58

